Free Trial

Dr. Martens (LON:DOCS) Shares Down 0% - Here's Why

Dr. Martens logo with Consumer Cyclical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares were effectively unchanged on the session (fell 0%)—last at GBX 62.69 after trading as low as GBX 61.70—with just 959,172 shares changing hands, down about 93% from the average, signaling very low intraday liquidity.
  • Brokerage sentiment is a consensus “Moderate Buy” (two Buys, two Holds) with a reported consensus price target of GBX 6,000.
  • Key fundamentals: market cap £605.98M, P/E 36.88 and a high debt-to-equity ratio of 120.66; the 50-day moving average (GBX 66.75) sits below the 200-day (GBX 77.78), indicating recent weakness.
  • Five stocks we like better than Dr. Martens.

Shares of Dr. Martens plc (LON:DOCS - Get Free Report) fell 0% on Tuesday . The stock traded as low as GBX 61.70 and last traded at GBX 62.69. 959,172 shares were traded during mid-day trading, a decline of 93% from the average session volume of 13,322,682 shares. The stock had previously closed at GBX 62.70.

Analyst Upgrades and Downgrades

DOCS has been the subject of a number of recent analyst reports. Royal Bank Of Canada reissued a "sector perform" rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Berenberg Bank reissued a "buy" rating on shares of Dr. Martens in a report on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 6,000.

Read Our Latest Analysis on DOCS

Dr. Martens Stock Down 0.0%

The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 120.66. The company has a market cap of £605.98 million, a P/E ratio of 36.88, a price-to-earnings-growth ratio of 6.40 and a beta of 0.20. The company has a fifty day moving average of GBX 66.75 and a 200 day moving average of GBX 77.78.

About Dr. Martens

(Get Free Report)

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dr. Martens Right Now?

Before you consider Dr. Martens, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.

While Dr. Martens currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines